The professor of translational dementia research at Newcastle University talked about late-breaking data presented at CTAD 2025 on neflamapimod in the phase 2b RewinD-LB trial. [WATCH TIME: 5 minutes]
Paul Taylor, MBBS, PhD, MRCPsych
Advertisement
Professor of translational dementia research at Newcastle University.
Articles by Paul Taylor, MBBS, PhD, MRCPsych
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis
2
FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS
3
Episode 156: Building Better Mood and Behavior Care for Parkinson Disease
4
Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care
5
